The present invention relates to novel triazine compounds, to processes forpreparing them, to a pharmaceutical composition comprising them, and to theuse thereof for the treatment of human cancers. The novel triazine compoundsare notable, compared to the known triazine compounds, for improved efficacywith simultaneously reduced toxicity, i.e. for lower side effects.